Answers are grounded in this paper and cite their sources.
Expert review addresses secondary graft function issues post-transplant in multiple myeloma, suggesting a new rescue method.
Secondary PGF after Auto-HSCT appears multifactorial, involving quantitatively adequate but qualitatively fragile grafts, inflammatory/microenvironmental injury, and therapy-related megakaryocytic vulnerability (including heavy lenalidomide exposure). When backup cells are available and reversible causes are excluded, early unpreconditioned autologous PBSC boost is a safe, feasible, and likely under-utilized salvage strategy. Strategic PBSC banking and early recognition may prevent life-threatening PGF.
No takes yet. Share an insight, caveat, or question.
You et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: